Non-small cell lung cancer
Conditions
Interventions
Sponsors
The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Pathologically and/or cytologically diagnose with IIIB-IVB non-small cell lung cancer; 2. Patients with negative driver genes who have received at least one type of systemic chemotherapy (including combined immune checkpoint inhibitors or anti-vascular drug therapy) have progressed, relapsed, or become intolerable; Patients with positive driver gene (EGFR mutation or ALK fusion positive) who have progressed, relapsed, or become intolerable after receiving corresponding standard targeted drug therapy; 3. Aged from 18 to 75 years, male or female; 4. Eastern Cooperative Oncology Group (ECOG) performance scale (PS) score of 0-2; 5. The expected survival time>=24 weeks; 6. A measurable lesion based on the RECIST criteria; 7. Adequate liver and kidney function (creatinine clearance rate>=60ml/min; total bilirubin100g/L, platelet count>100x10^9/L, neutrophils>1.5x10^9/L; 9. Agree to contraception during the trial and within six months after the trial ends; 10. Patients or their family members signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. With unstable brain metastases or at risk of bleeding after being evaluated by researchers; 2. Previously used anlotinib or apatinib; 3. Concomitant with other types of malignant tumors; 4. Difficulties with oral medications (such as dysphagia, chronic diarrhea, and intestinal obstruction); 5. Female patients with positive pregnancy test results 7 days before enrollment; 6. Women who are pregnant or breastfeeding; 7. Patients with mental illness or mental retardation; 8. Allergy or intolerance to the study drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective Response Rate;Overall survival;Patient-reported Outcome;Disease Control Rate; | — |
Countries
China
Contacts
Public ContactLin Lizhu
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Outcome results
None listed